Get a preview of Chile Connected's anticipated HealthTech panel

Q&A

Get ready for a fascinating panel. Photo by WebPhotographeer/Getty

The technology and innovation portion of Chile Connected begins next week, and if you haven't already reserved your free spot for the virtual event, you'd be wise to go do it now.

From October 27-29, you can hear from high-level experts and keynote speakers from both Chile and the U.S, as well as network and make new connections that will hopefully lead to a successful partnership.

Josh Sol, the administrative director of Houston Methodist Innovation and Ambulatory Clinical Systems, will be moderating the panel on October 29. The topic is "The Present Future of HealthTech," and will address what COVID-19 means for the future of healthcare technology.

Panelists include Daniela Mendoza, commercial manager for GenoSUR; Alberto Rodríguez-Navarro, founder of Levita Magnetics; and John Dvor, managing director of Miraki Innovation.

InnovationMap recently spoke with Sol about the upcoming event.

InnovationMap: What can U.S. companies gain from participating in this session?

Josh Sol: U.S. companies have the opportunity to gain additional perspectives from other like-minded individuals who are passionate about technology. I've been impressed from the groups and ProChile representatives I have spoken with to date, and I look forward to hearing more about innovation efforts coming from a leading Latin American technology epicenter.

IM: How important are international partnerships in the health tech sector?

JS: Innovation in healthcare technology is coming from all over the globe. Cultural experiences tend to drive creation and innovation. When we collaborate with partners outside of the U.S., we have the opportunity to broaden opportunities and learn from other cultures, and, in turn, we have the potential to apply those insights to what our standard processes are within the U.S. healthcare system.

IM: Personally, why did you feel it important to be involved with Chile Connected?

JS: I have been so impressed by the passion coming from Chile Connected. Discovering new companies doing amazing things in the healthcare technology space continues to fuel my passion for what I do on a day-to-day basis.

IM: What are the key ways businesses can adapt in the pandemic environment?

JS: Businesses should be as nimble as they can — that's a pretty universal lesson most have experienced and we've certainly had first-hand experience in this area as well. At Houston Methodist, our focus is always keeping the patient at the center of everything we do, and we appreciate the collaborative business partners who help us maintain our commitment to our patients, the community, and our clinicians during the pandemic.

Some partners have even pivoted their technology offerings to align with the challenges spurred by COVID. Some areas where we have had to adapt during COVID include ramping up our telemedicine efforts, quickly turning on our virtual ICU, and diversifying the way we communicate with our patients through digital technology.

IM: What do you think is important for start-ups to focus on when trying to grow in this field?

JS: Healthcare technology organizations have many opportunities available to them and must be open to change and the innovations coming from younger start-up companies. As a start-up, it's important to know the problem you are attempting to solve, and to also understand the bigger picture of either the process, patient experience, or clinician experience you are impacting.

Too often, a company will say, "What do you want it to do? It can do anything…" Always come with a solution mindset. Drill down into your offering and what value you have to the organization you're pitching to.

Reserve your free spot for Chile Connected now.

Form international partnerships without ever leaving home. Photo by Luis Alvarez/Getty

5 reasons to get connected with Chile via this virtual event

Listen to the List

It's almost time for the tech and innovation portion of Chile Connected, a nearly month-long virtual event designed to serve as a "matchmaker" for technology firms as well as creative industries, healthy food providers, and women-led businesses.

Sponsored by ProChile, the online convention is an easy — and free — way to meet your next possible collaborator, all from the comfort of home.

To make sure you don't miss your shot at building the next big partnership, here's everything you need to know.

1. The when and where
Chile Connected runs online October 19-November 20, with the tech and innovation panels taking place October 27-29. It's free to attend and you can register here.

2. What to expect
In addition to B2B matchmaking sessions, you can hear Chilean entrepreneurs about about their global innovations in the areas of HealthTech, FinTech, EdTech, and RetailTech. Experts will explore the future of e-commerce, how to empower women in tech, and how healthcare technology is changing in the face of COVID-19.

3. Who'll be there

  • HealthTech: Alberto Rodriguez, president of Levita Magnetic, a company that develops technology through magnets to reduce the need for incisions, invasive surgeries, and scars.
  • RetailTech: Ariel Schilkrut, cofounder of Zippedi Inc. Zippedi is a robot that uses AI to provide services to the retail industry. It includes image recognition and deep learning to create inventories, which improves the efficiency of replenishment processes and the level of service that these companies provide to their customers.
  • EdTech: Komal Dadlani, CEO and cofounder of Lab4U, a company that transforms mobile devices into scientific instruments to democratize access to science, giving the possibility of having a laboratory in your pockets.
  • EdTech: Marisol Alarcón from social de Laboratoria, a company that trains women without higher education as web developers. This undertaking was highlighted by Mark Zuckerberg and Barack Obama for its contribution to gender equality.
  • Fintech: Cristóbal Forno, founding partner of Global 66, a platform for international money transfers.

But that's just the start — besides the big names from even bigger companies, there will be dozens of people from all over the world looking to network and form partnerships.

4. Why you should consider Chile
Chile is recognized as the most advanced IT market in Latin America, with the IT sector there representing 3.4 percent of its national GDP. Chile is also the 29th largest trading partner of the United States, while America is the No. 1 destination for non-copper goods and service exports from Chile.

5. How Chile benefits you
Most Chilean companies — 53 percent, in fact — are looking for a joint venture or capital to grow into other markets. Chile has been regularly investing not only money but also resources and programs to support new startups and companies. Start-up Chile is one such accelerator; it has vowed to invest $80,000 in an American start-up that will create and develop its idea in Chile.

Reserve your free spot for Chile Connected now.

Your next game-changing parter might be in Chile. Photo by Klaus Vedfelt/Getty

Why your tech company should partner with forward-thinking Chile

Find Your Match

What's one of the most important ways a tech company can ensure success? Collaboration. Finding that perfect fit with a like-minded partner just might change the world — but first you have to find each other.

For many U.S.-based companies, their next great collab could be Chile. The South American country has recently been attracting the attention of big-name players such as Jeff Bezos, all based off its growing IT presence and expansion in the HealthTech, FinTech, EdTech, and RetailTech sectors.

But you don't have to actually travel to Chile to meet possible partners.

Chile Connected, sponsored by ProChile, is a nearly month-long virtual event designed to serve as a "matchmaker" for technology firms as well as creative industries, healthy food providers, and women-led businesses. And it's completely free to attend.

On October 27-29, the tech and innovation panel will welcome high-level experts and keynote speakers from both Chile and the U.S.

You'll hear from top-level execs at rapidly growing companies like biotech start-up GenoSUR and magnetics surgery pioneer Levita, both Chilean-based with American partnerships. Levita founder Alberto Rodriguez-Navarro will share the stage with GenoSUR's commercial manager Daniela Mendoza, along with a representative from CIC Health, which is innovating in COVID-19 rapid testing.

You also get to network and make new connections, hopefully leading to a successful partnership.

Most Chilean companies — 53 percent, in fact — are looking for a joint venture or capital to grow into other markets. U.S. companies then get the opportunity to select those which best suit their needs or have the most potential, as well as purchase up-and-coming software and other tech products at a very competitive price.

Chile has been regularly investing not only money but also resources and programs to support new startups and companies. Start-up Chile is one such accelerator that has vowed to invest $80,000 in an American start-up that will create and develop its idea in Chile.

So the money, know-how, and support are just waiting in Chile for the American businesses to come find it, and Chile Connected is where you can get started. Reserve your free spot for the event here.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

How Houston's innovation sector fared in 2025 Texas legislative session

That's a Wrap

The Greater Houston Partnership is touting a number of victories during the recently concluded Texas legislative session that will or could benefit the Houston area. They range from billions of dollars for dementia research to millions of dollars for energy projects.

“These wins were only possible through deep collaboration, among our coalition partners, elected officials, business and community leaders, and the engaged members of the Partnership,” according to a partnership blog post. “Together, we’ve demonstrated how a united voice for Houston helps drive results that benefit all Texans.”

In terms of business innovation, legislators carved out $715 million for nuclear, semiconductor, and other economic development projects, and a potential $1 billion pool of tax incentives through 2029 to support research-and-development projects. The partnership said these investments “position Houston and Texas for long-term growth.”

Dementia institute

One of the biggest legislative wins cited by the Greater Houston Partnership was passage of legislation sponsored by Sen. Joan Huffman, a Houston Republican, to provide $3 billion in funding over 10 years for the Dementia Prevention and Research Institute of Texas. Voters will be asked in November to vote on a ballot initiative that would set aside $3 billion for the new institute.

The dementia institute would be structured much like the Cancer Prevention and Research Institute of Texas (CPRIT), a state agency that provides funding for cancer research in the Lone Star State. Since its founding in 2008, CPRIT has awarded nearly $3.9 billion in research grants.

“By establishing the Dementia Prevention and Research Institute of Texas, we are positioning our state to lead the charge against one of the most devastating health challenges of our time,” Huffman said. “With $3 billion in funding over the next decade, we will drive critical research, develop new strategies for prevention and treatment, and support our healthcare community. Now, it’s up to voters to ensure this initiative moves forward.”

More than 500,000 Texans suffer from some form of dementia, including Alzheimer’s disease, according to Lt. Gov. Dan Patrick.

“With a steadfast commitment, Texas has the potential to become a world leader in combating [dementia] through the search for effective treatments and, ultimately, a cure,” Patrick said.

Funding for education

In the K-12 sector, lawmakers earmarked an extra $195 million for Houston ISD, $126.7 million for Cypress-Fairbanks ISD, $103.1 million for Katy ISD, $80.6 million for Fort Bend ISD, and $61 million for Aldine ISD, the partnership said.

In higher education, legislators allocated:

     
  • $1.17 billion for the University of Houston College of Medicine, University of Texas Health Science Center at Houston, UT MD Anderson Cancer Center, and Baylor College of Medicine
  • $922 million for the University of Houston System
  • $167 million for Texas Southern University
  • $10 million for the Center for Biotechnology at San Jacinto College.

Infrastructure

In the infrastructure arena, state lawmakers:

     
  • Approved $265 million for Houston-area water and flood mitigation projects, including $100 million for the Lynchburg Pump Station
  • Created the Lake Houston Dredging and Maintenance District
  • Established a fund for the Gulf Coast Protection District to supply $550 million for projects to make the coastline and ship channel more resilient

"Nuclear power renaissance"

House Bill 14 (HB 14) aims to lead a “nuclear power renaissance in the United States,” according to Texas Gov. Greg Abbott’s office. HB 14 establishes the Texas Advanced Nuclear Energy Office, and allocates $350 million for nuclear development and deployment. Two nuclear power plants currently operate in Texas, generating 10 percent of the energy that feeds the Electric Reliability Council Texas (ERCOT) power grid.

“This initiative will also strengthen Texas’ nuclear manufacturing capacity, rebuild a domestic fuel cycle supply chain, and train the future nuclear workforce,” Abbott said in a news release earlier this year.

One of the beneficiaries of Texas’ nuclear push could be Washington, D.C.-based Last Energy, which plans to build 30 micro-nuclear reactors near Abilene to serve power-gobbling data centers across the state. Houston-based Pelican Energy Partners also might be able to take advantage of the legislation after raising a $450 million fund to invest in companies that supply nuclear energy services and equipment.

Reed Clay, president of the Texas Nuclear Alliance, called this legislation “the most important nuclear development program of any state.”

“It is a giant leap forward for Texas and the United States, whose nuclear program was all but dead for decades,” said Clay. “With the passage of HB 14 and associated legislation, Texas is now positioned to lead a nuclear renaissance that is rightly seen as imperative for the energy security and national security of the United States.”

---

A version of this article first appeared on EnergyCapitalHTX.com.

View All Listings